Skip Navigation
Meet the CEO

Mark Levick

Alvotech was founded in 2013, with the clear mission to become a global leader in Biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. We have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product.

Our commitment

Our in-house development and manufacturing platform located at four sites across Europe drives timely development of a strong and differentiated portfolio, while our state-of-theart flexible manufacturing facility ensures high quality and cost-effective production. We are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. We believe in focus and specialization and each of our 400 professionals share our passion and pride to be part of this mission.

Through dedication and hard work, we will become a leading global biosimilar company. Our commitment to our partners is to be the best, most flexible supplier, with the capability to adapt to changing market demands. These elements are the key to Alvotech’s success.

Meet management

Alvotech brings together a group of senior pharmaceutical executives with broad backgrounds and extensive experience in the biopharmaceutical industry. The leadership team is led by Mark Levick, CEO, and is supported by a Board of Directors composed of experts in their fields.